Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
AssigneeTrustees of Tufts College
InventorsLouis Shuster, Nicholas H. Dodman
Life of this patent
Estimating the term…
Abstract
NMDA receptor antagonists can be used in methods of treatment, for reducing the frequency of stereotypic behaviors in animals and for reducing the frequency of analogous compulsive behaviors in humans, for example, those that have been said to be a manifestation of, or related to, obsessive-compulsive disorder. Of particular interest are the (+) enantiomers of opioid receptor binding compounds, which can reduce the frequency of the behaviors, while having no effects from binding at the opioid receptor.
Claims33
A method for treating the obsessive-compulsive components of Tourette syndrome in a human, comprising administering to the human an effective amount of a composition comprising one or more NMDA receptor antagonists, wherein the composition does not comprise haloperidol and does not comprise (−) naloxone.
A method for treating the obsessive-compulsive components of Tourette syndrome in a human, comprising administering to the human an effective amount of a composition comprising one or more NMDA receptor antagonists, wherein the composition does not comprise haloperidol and does not comprise primarily (−) enantiomer of an opioid receptor agonist or antagonist.
A method for treating the obsessive-compulsive components of trichotillomania in a human, comprising administering to the human an effective amount of a composition comprising one or more NMDA receptor antagonists, wherein the composition does not comprise haloperidol.
A method for treating the obsessive-compulsive components of stereotypic movement disorder in a human, comprising administering to the human an effective amount of a composition comprising one or more NMDA receptor antagonists.
A method for treating the obsessive-compulsive components of smoking in a human, comprising administering to the human an effective amount of a composition comprising one or more NMDA receptor antagonists.
A method for treating the obsessive-compulsive components of excoriation in a human, comprising administering to the human an effective amount of a composition comprising one or more NMDA receptor antagonists, wherein the composition does not comprise (−) naltrexone.
A method for treating the obsessive-compulsive components of alcoholism in a human, comprising administering to the human an effective amount of a composition comprising one or more compounds selected from the group consisting of:
- dextromethorphan, dextrorphan, naltrexone, naloxone, methadone, pentazocine, nalmefene, diprenorphine, nalorphine, hydromorphone, oxymorphone, hydrocodone, oxycodone, buprenorphine, butorphanol, nalbuphine, fentanyl, metazocine, cyclazocine, etazocine, and a combination of any of the preceding, wherein the compounds are predominantly (+) enantiomer.
A method for treating the obsessive-compulsive components of opioid addiction in a human, comprising administering to the human an effective amount of a composition comprising one or more compounds selected from the group consisting of:
- dextromethorphan, dextrorphan, naltrexone, naloxone, methadone, pentazocine, nalmefene, diprenorphine, nalorphine, hydromorphone, oxymorphone, hydrocodone, oxycodone, buprenorphine, butorphanol, nalbuphine, fentanyl, metazocine, cyclazocine, etazocine, and a combination of any of the preceding, wherein the compounds are predominantly (+) enantiomer.
A method for treating the obsessive-compulsive components of scratching in a human, comprising administering to the human an effective amount of a composition comprising one or more NMDA receptor antagonists.
A method for treating the obsessive-compulsive components of pruritis in a human, comprising administering to the human an effective amount of a composition comprising one or more NMDA receptor antagonists.
Dependencies are inferred from the claim text.